Treatment of NSCLC Brain Metastases

Patient Selection and Treatment Approach

The American Society of Clinical Oncology recommends whole brain radiation therapy (WBRT) for NSCLC patients with more than 3-4 brain metastases who have favorable prognostic features (RPA class I-II), while stereotactic radiosurgery (SRS) alone is preferred for 1-4 metastases 1, 2, 3, 4, 5, 6
For RPA Class I patients, age <65 years, Karnofsky Index (KI) ≥70%, no extracranial metastases, and controlled primary tumor are recommended for treatment 2, 4, 5, 6
For RPA Class II patients, all other patients with KI ≥70% are recommended for treatment 2, 4, 5, 6
For patients with KI <70%, WBRT should NOT be offered due to dismal prognosis (median survival <2 months); only best supportive care is recommended 1, 3, 7, 8

For single brain metastasis, surgery or SRS alone is the recommended treatment for RPA class I-II patients 1, 2, 3, 4, 5, 6
For 2-4 brain metastases, SRS alone is the preferred treatment for RPA class I-II patients 1, 3, 8, 9
For more than 3-4 brain metastases, WBRT is recommended when more than 3 brain metastases are diagnosed in RPA class I-II patients 1, 3

Asymptomatic brain metastases should not be routinely treated with radiotherapy; deferred irradiation upon progression is a valuable option 1, 3
Systemic therapy with deferred WBRT should be considered in patients with asymptomatic brain metastases who have not received prior systemic therapy 2, 4, 5, 6
For patients with asymptomatic brain metastases and specific molecular alterations, local therapy may be delayed until intracranial progression 9
EGFR-mutant NSCLC patients may be offered osimertinib or icotinib 9
ALK-rearranged NSCLC patients may be offered alectinib, brigatinib, or ceritinib 8, 9, 10
PD-L1-expressing NSCLC patients may be offered pembrolizumab with pemetrexed and platinum agent 9, 10

For symptomatic brain metastases and/or significant edema, dexamethasone 4 mg/day (or equivalent corticosteroid) is recommended 1, 3, 4, 5, 6, 8
Early tapering after radiotherapy is essential 1, 3, 4, 5, 6
Corticosteroids are NOT recommended for asymptomatic brain metastases 2, 4, 5, 6

Patients with multiple brain metastases, a controlled primary tumor, no extracranial disease, and a Karnofsky Performance Status ≥ 70 are classified as RPA Class I according to the RTOG recursive partitioning analysis derived from >1,200 patients. [National Comprehensive Cancer Network] 11, 12, 13, 14

30 Gy in 10 daily fractions is the standard WBRT schedule endorsed by contemporary NCCN guidelines for patients with ≥ 3–4 brain metastases and RPA Class I–II status. [National Comprehensive Cancer Network] 15, 16, 12
37.5 Gy in 15 daily fractions of 2.5 Gy is an acceptable alternative used at some centers, though it is not the primary guideline‑recommended regimen. [National Comprehensive Cancer Network] 15

Memantine should be offered to patients receiving WBRT who have no hippocampal lesions and an expected survival of ≥ 4 months, as it reduces the risk of cognitive decline without compromising tumor control. [National Comprehensive Cancer Network] 17
Hippocampal‑avoidance WBRT should be employed under the same conditions (no hippocampal involvement, ≥ 4 months expected survival) to further protect neurocognitive function. [National Comprehensive Cancer Network] 17
The combination of memantine and hippocampal avoidance has been shown to significantly lessen cognitive deterioration while maintaining oncologic efficacy. [National Comprehensive Cancer Network] 17

Median overall survival after WBRT for RPA Class I patients is approximately 7.1 months. [National Comprehensive Cancer Network] 11, 12, 13, 14
RPA Class I represents the best‑prognosis subgroup among patients with brain metastases. [National Comprehensive Cancer Network] 11, 12, 13, 14